Endophthalmitis is one of the most feared complications of ocular trauma or surgery. It is a complex pathogen- and host-mediated process that often results in significant vision loss. This review summarizes data from experimental models of staphylococcal endophthalmitis that address the host’s immune response to intraocular staphylococci and those that investigate disease pathogenesis.

Keywords:
Endophthalmitis, Immune response, Rabbit, Rat, Staphylococci, Toxins
1.
Carney M, Peyman GA: Vitrectomy in endophthalmitis. Int Ophthalmol Clin 1987;27:127–134.
2.
Rowsey JJ, Newsom DL, Sexton DJ, Harms WK: Endophthalmitis: Current approaches. Ophthalmology 1982;89:1055–1066.
3.
Mandelbaum S, Forster RK: Postoperative endophthalmitis. Int Ophthalmol Clin 1987;27:95–106.
4.
Klimek JJ, Ajemian E, Andrews L, Hryb K, Hill DA: Outbreak of bacterial endophthalmitis after cataract surgery and lens implantation: Lack of direct evidence for exogenous contributing factors. Am J Infect Control 1986;14:184–187.
5.
Weber DJ, Hoffman KL, Throft RA, Baker AS: Endophthalmitis following intraocular lens implantation: Report of 30 cases and review of the literature. Rev Infect Dis 1986;8:12–20.
6.
Brod RD, Flynn HW Jr: Infectious endophthalmitis. Curr Opin Infect Dis 1997;10:153–162.
7.
Javitt JC, Vitale S, Canner JK, Street DA, Krakauer H, McBean AM, Sommer A: Natural outcomes of cataract extraction. Endophthalmitis following inpatient surgery. Arch Ophthalmol 1991;109:1085–1089.
8.
Montan PG, Koranyi G, Setterquist HE, Stridh A, Philipson BT, Wiklund K: Endophthalmitis after cataract surgery: Risk factors relating to technique and events of the operation and patient history. Ophthalmology 1998;105:2171–2177.
9.
Boldt HC, Pulido JS, Blodi CF, Folk JC, Weingeist TA: Rural endophthalmitis. Ophthalmology 1989;96:1722–1726.
10.
Sassani JW, Yanoff M, Fine BS: Nongranulomatous inflammation: Uveitis, endophthalmitis, panophthalmitis and sequelae; in Tasman W, Jaeger EA (eds): Duane’s Foundations of Clinical Ophthalmology. Philadelphia, Lippincott, 1991, vol 3, pp 1–25.
11.
Jacobs DR, Cohen HB: The inflammatory role of endotoxin in rabbit gram-negative bacterial endophthalmitis. Invest Ophthalmol Vis Sci 1984;25:1074–1079.
12.
Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH, Kelsey SF: Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996;122:1–17.
13.
Forster RK: Experimental postoperative endophthalmitis. Trans Am Ophthalmol Soc 1992;90:505–559.
14.
Kuby J: Immunology. New York, Freeman, 1997, pp 3–24.
15.
Verbrugh HA, van Dijk WC, Peters R, van Erne ME, Daha MR, Peterson PK, Verhoef J: Opsonic recognition of staphylococci mediated by cell wall peptidoglycan: Antibody-independent activation of human complement and opsonic activity of peptidoglycan antibodies. J Immunol 1989;124:1167–1173.
16.
Abbas AK, Lichtman AH, Poper JS: The complement system; in Abbas AK, Lichtman AH, Poper JS (eds): Cellular and Molecular Immunology, ed 3. Philadelphia, Saunders, 1997, pp 314–338.
17.
Roitt I, Brostoff J, Male D: Complement; in Roitt I, Brostoff J, Male D (eds): Immunology, ed 3. London, Mosby-Year Book, 1993, pp 12–15.
18.
de Bustros S, Michels RG, Glaser BM: Evolving concepts in the management of posterior segment penetrating ocular injuries. Retina 1990;10(suppl ):S72–S75.
19.
Mondino BJ, Zaidman GW: Hemolytic complement in tears. Ophthalmic Res 1983;15:208–211.
20.
Streilein JW: Immunoregulatory mechanisms of the eye. Prog Retin Eye Res 1999;18:357–370.
21.
Atherton SS, Pesicka GA, Streilein JW: Retinitis and deviant immune responses following intravitreal inoculation of HSV-1. Invest Ophthalmol Vis Sci 1987;28:859–866.
22.
Niederkorn JY, Streilein JW: Intracamerally induced concomitant immunity: Mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge. J Immunol 1983;131:2587–2594.
23.
Cunha-Vaz J: The blood-ocular barriers. Surv Ophthalmol 1979;23:279–296.
24.
Kloss WE, Bannerman TL: Update on clinical significance of coagulase-negative staphylococci. Clin Microbiol Rev 1994;7:117–140.
25.
Joklik WK, Willett HP, Amos DB, Wilfert CM: Composition, structure and biosynthesis of bacterial cell envelope and energy storage polymers; in Joklik WK, Willett HP, Amos DB, Wilfert CM (eds): Zinsser Microbiology, ed 20. East Norwalk, Appleton & Lange, 1992, pp 76–93.
26.
Huebner J, Goldmann DA: Coagulase negative staphylococci: Role as pathogens. Annu Rev Med 1999;50:223–236.
27.
Pinna A, Zanetti S, Sotgiu M, Sechi LA, Fadda G, Carta F: Identification and antibiotic susceptibility of coagulase negative staphylococci isolated in corneal/external infections. Br J Ophthalmol 1999;83:771–773.
28.
Salyers AA, Whitt DD: Bacterial Pathogenesis: A Molecular Approach. Washington, ASM Press, 1994.
29.
Theodore FH: Bacterial endophthalmitis after cataract surgery. Int Ophthalmol Clin 1964;4:839–859.
30.
Valenton MJ, Brubaker RF, Allen HF: Staphylococcus epidermidis (albus) endophthalmitis: Report of two cases after cataract extraction. Arch Ophthalmol 1973;89:94–96.
31.
Rupp ME: Coagulase-negative staphylococcal infections: An update regarding recognition and management. Curr Clin Top Infect Dis 1997;17:51–87.
32.
Mack D: Molecular mechanisms of Staphylococcus epidermidis biofilm formation. J Hosp Infect 1999;43(suppl):S113–125.
33.
Crossley KB, Archer GL (eds): The Staphylococci in Human Disease. New York, Churchill-Livingstone, 1997.
34.
Gemmell CG, Schumacher-Perdreau F: Extracellular toxins and enzymes elaborated by coagulase-negative staphylococci; in Mårdh P-A, Schleifer KH (eds): Coagulase-Negative Staphylococci. Stockholm, Almquist & Wiksell, 1986, pp 109–121.
35.
Wadström T, Rozgonyi F: Virulence determinants of coagulase-negative staphylococci; in Mårdh P-A, Schleifer KH (eds): Coagulase-Negative Staphylococci. Stockholm, Almquist & Wiksell, 1986, pp 125–130.
36.
Iandolo JJ: Genetic analysis of extracellular toxins of Staphylococcus aureus. Annu Rev Microbiol 1989;43:375–402.
37.
Projan SJ, Novick RP: The molecular basis of pathogenicity; in Crossley KB, Archer GL (eds): The Staphylococci in Human Disease. New York, Churchill Livingstone, 1997, pp 55–81.
38.
Yanda JM: Elastolytic activity among staphylococci. J Clin Microbiol 1986;24:945–946.
39.
Noble MA, Grant SK, Hajen E: Characterization of a neutrophil-inhibitory factor from clinically significant Staphylococcus epidermidis. J Infect Dis 1990;162:909–913.
40.
Wu PZJ, Zhu H, Thakur A, Willcox MDP: Comparison of potential pathogenic traits of staphylococci that may contribute to corneal ulceration and inflammation. Aust NZ J Ophthalmol 1999;27:234–236.
41.
Males B, Rogers WA, Parisi JT: Virulence factors of biotypes of Staphylococcus epidermidis from clinical sources. J Clin Microbiol 1975;1:256–261.
42.
Patrick CC, Hetherington SV, Roberson PK, Henwick S, Sloas MM: Comparative virulence of Staphylococcus epidermidis isolates in a murine catheter model. Pediatr Res 1995;37:70–74.
43.
Gray ED, Peters M, Vertegen M, Regelmann WE: Effect of extracellular slime substance from Staphylococcus epidermidis on the cellular immune response. Lancet 1984;i:365–367.
44.
Stout RD, Ferguson KP, Li Y-N, Lambe DW Jr: Staphylococcal exopolysaccharides inhibit lymphocyte proliferative responses by activation of monocyte prostaglandin production. Infect Immun 1992;60:922–927.
45.
Beutler B, Cerami A: The biology of cachectic/TNF-α: A primary mediator of the host response. Annu Rev Immunol 1989;7:625–656.
46.
Dinarello CA: Interleukin 1 and its biologically related cytokines. Adv Immunol 1989;44:153–206.
47.
Gray ED, Regelmann WE, Peters G: Staphylococcal slime and host defenses: Effects on lymphocytes and immune function; in Pulverer G, Quie PG, Peters G (eds): Pathogenicity and Clinical Significance of Coagulase-Negative Staphylococci. Stuttgart, Fischer, 1989, pp 45–54.
48.
Mattsson E, Rollof J, Verhoef J, van Dijk H, Fleer A: Serum-induced potentiation of tumor necrosis factor alpha production by human monocytes in response to staphylococcal peptidoglycan: Involvement of different serum factors. Infect Immun 1994;62:3837–3843.
49.
Wakabayushi G, Gelfand JA, Jung WK, Connolly RJ, Burke JF, Dinarello CA: Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia, comparison to Escherichia coli. J Clin Invest 1991;87:1925–1935.
50.
DeVos AF, van Haren MAC, Verhagen C, Hoekzema R, Kijlstra A: Tumour necrosis factor-induced uveitis in the Lewis rat is associated with intraocular interleukin 6 production. Exp Eye Res 1995;60:199–207.
51.
Fleisher LN, Ferrell JB, McGahan C: Synergistic effects of tumor necrosis factor-α and interleukin 1-β. Invest Ophthalmol Vis Sci 1992;33:2120–2127.
52.
Nayak N, Satpathy G: Slime production as a virulence factor in Staphylococcus epidermidis isolated from bacterial keratitis. Indian J Med Res 2000;111:6–10.
53.
Sloot N, Thomas M, Marre R, Gatermann S: Purification and characterization of elastase from Staphylococcus epidermidis. J Med Microbiol 1992;37:201–205.
54.
Götz F, Verheij HM, Rosenstein R: Staphylococcal lipases: Molecular characterisation, secretion and processing. Chem Phys Lipids 1998;93:15–25.
55.
Mahajan VM, Reddy TN, Agarwal LP: Toxigenic strains of Staphylococcus epidermidis and their experimental corneal pathogenicity in rabbits. Int Ophthalmol 1982;5:155–161.
56.
Scheifele DW, Bjornson GL: Delta toxin activity in coagulase-negative staphylococci from the bowels of neonates. J Clin Microbiol 1988;26:279–282.
57.
Gupta S, Morris JG Jr, Paniarali P, Nataro JP, Glass RI, Gewolb IH: Endemic necrotizing enterocolitis: Lack of association with a specific infectious agent. Pediatr Infect Dis J 1994;13:728–734.
58.
Gemmell CG: Virulence characteristics of Staphylococcus epidermidis. J Med Microbiol 1986;22:287–289.
59.
Lowy FD: Staphylococcus aureus infections. N Engl J Med 1998;339:520–532.
60.
Wang JE, Jørgensen PF, Almlöf M, Thiemermann C, Foster SJ, Aasen AO, Solberg R: Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model. Infect Immun 2000;68:3965–3970.
61.
Rotta J: Endotoxin-like properties of the peptidoglycan. Z Immunitätsforsch Exp Klin Immunol 1975;149:230–244.
62.
Willett HP: Staphylococcus; in Joklik WK, Willett HP, Amos DB, Wilfert CM (eds): Zinsser Microbiology, ed 20. Norwalk, Appleton & Lange, 1992, pp 401–416.
63.
Recsei P, Kreiswirth B, O’Reilly M, Schlievert P, Gruss A, Novick RP: Regulation of exoprotein gene expression in Staphylococcus aureus by agr. Mol Gen Genet 1986;202:58–61.
64.
Cheung AL, Koomey JM, Butler CA, Projan SJ: Regulation of exoprotein expression in Staphylococcus aureus by a locus (sar) distinct from agr. Proc Natl Acad Sci USA 1992;89:6462–6466.
65.
Smeltzer MS, Hart ME, Iandolo JJ: Phenotypic characterization of xpr, a global regulator of extracellular virulence factors in Staphylococcus aureus. Infect Immun 1993;61:919–925.
66.
Cheung AL, Eberhardt KJ, Chung E, Yeaman MR, Sullam PM, Ramos M, Bayer AS: Diminished virulence of a sar–/agr– mutant of Staphylococcus aureus in the rabbit model of endocarditis. J Clin Invest 1994;94:1815–1822.
67.
Abdelnour A, Arvidson S, Bremell T, Rydén C, Tarkowski A: The accessory gene regulator [agr] controls Staphylococcus aureus virulence in a murine arthritis model. Infect Immun 1993;61:3879–3885.
68.
Vuong C, Götz F, Otto M: Construction and characterization of an agr deletion mutant of Staphylococcus epidermidis. Infect Immun 2000;68:1048–1053.
69.
Fluckiger U, Wolz C, Cheung AL: Characterization of a sar homolog of Staphylococcus epidermidis. Infect Immun 1998;66:2871–2878.
70.
Driebe WT Jr, Mandelbaum S, Forster RK, Schwartz LK, Culbertson WW: Pseudophakic endophthalmitis: Diagnosis and management. Ophthalmology 1986;93:442–448.
71.
Shrader SK, Band JD, Lauter CB, Murphy P: The clinical spectrum of endophthalmitis: Incidence, predisposing factors, and features influencing outcome. J Infect Dis 1990;162:115–120.
72.
Nobe JR, Gomezu DS, Liggett P, Smith RE, Robin JB: Post-traumatic and postoperative endophthalmitis: A comparison of visual outcomes. Br J Ophthalmol 1987;71:614–617.
73.
Seedor JA, Koplin RS, Shah M, Almeda EE, Perry HD: Chronic postoperative endophthalmitis from Staphylococcus aureus. J Cataract Refract Surg 1990;16:512–513.
74.
Speaker MG, Milch FA, Shah MK, Eisner W, Kreiswirth BN: Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology 1991;98:639–650.
75.
Bannerman TL, Rhoden DL, McAllister SK, Miller JM, Wilson LA: The source of coagulase-negative staphylococci in the endophthalmitis vitrectomy study: A comparison of eyelid and intraocular isolates using pulsed-field gel electrophoresis. Arch Ophthalmol 1997;115:357–361.
76.
Groden LR, Murphy B, Rodnite J, Genvert GI: Lid flora in blepharitis. Cornea 1991;10:50–53.
77.
Mahajan VM: Acute bacterial infection of the eye: Their etiology and treatment. Br J Ophthalmol 1983;67:191–194.
78.
Mao LK, Flynn HW Jr, Miller D, Pflugfelder SC: Endophthalmitis caused by Staphylococcus aureus. Am J Ophthalmol 1993;116:584–589.
79.
Olsen JC, Flynn HW, Forster RK, Culbertson WW: Results in the treatment of postoperative endophthalmitis. Ophthalmology 1983;90:692–699.
80.
Kattan HM, Flynn HW, Pflugfelder SC, Robertson C, Forster RK: Nosocomial endophthalmitis survey: Current incidence of infection after intraocular surgery. Ophthalmology 1991;98:227–238.
81.
Puliafito CA, Baker AS, Haaf J, Foster CS: Infectious endophthalmitis: Review of 36 cases. Ophthalmology 1982;89:921–929.
82.
Affeldt JC, Flynn HW Jr, Forster RK, Mandelbaum S, Clarksson JG, Jarus GD: Microbial endophthalmitis resulting from ocular trauma. Ophthalmology 1987;94:407–413.
83.
Bohigian GM, Olk RJ: Factors associated with a poor visual result in endophthalmitis. Am J Ophthalmol 1986;101:332–334.
84.
Ormerod LD, Ho DD, Becker LE, Cruise RJ, Grohar HI, Paton BG, Frederick AR Jr, Topping TM, Weiter JJ, Buzney SM, Ling RA, Baker AS: Endophthalmitis caused by coagulase-negative staphylococci. 1. Disease spectrum and outcome. Ophthalmology 1993;100:715–723.
85.
Ormerod LD, Becker LE, Cruise RJ, Grohar HI, Paton BG, Frederick AR Jr, Topping TM, Weiter JJ, Buzney SM, Baker AS: Endophthalmitis caused by coagulase-negative staphylococci. 2. Factors influencing presentation after cataract surgery. Ophthalmology 1993;100:724–729.
86.
Maylath FR, Leopold IH: Study of experimental intraocular infection. I. The recoverability of organisms inoculated into ocular tissues and fluids. II. The influence of antibiotics and cortisone, alone and combined, on intraocular growth of these organisms. Am J Ophthalmol 1955;40:86–101.
87.
Tucker DN, Forster RK: Experimental bacterial endophthalmitis. Arch Ophthalmol 1972;88:647–649.
88.
Koul S, Philipson A, Arvidson S: Role of aqueous and vitreous cultures in diagnosing infectious endophthalmitis. Acta Ophthalmol 1990;68:466–469.
89.
Flynn HW, Brod RD, Pflugfelder SC, Miller D: Endophthalmitis Management; in Duane TD (ed): Clinical Ophthalmology. Philadelphia, Harper & Row, 1994, vol 6, chapter 64.
90.
Wong IG, Ostler HB, Swan I: Reduced intraocular glucose in bacterial endophthalmitis. ARVO abstracts. Invest Ophthalmol Vis Sci 1980;19(suppl):51.
91.
Garretson BR, Deutsch TA, Ernest JT, Vernot JJ: Vitreous glucose in bacterial and sterile endophthalmitis. Invest Ophthalmol Vis Sci 1986;27:1541–1543.
92.
Beyer TL, Vogler G, Sharma D, O’Donnell FE: Protective barrier effect of the posterior lens capsule in exogenous bacterial endophthalmitis: An experimental primate study. Invest Ophthalmol Vis Sci 1984;25:108–112.
93.
Beyer TL, O’Donnell FE, Goncalves V, Singh R: Role of the posterior capsule in the prevention of postoperative bacterial endophthalmitis: Experimental primate studies and clinical implications. Br J Ophthalmol 1985;69:841–846.
94.
Records RE, Iwen PC: Experimental bacterial endophthalmitis following extracapsular lens extraction. Exp Eye Res 1989;49:729–737.
95.
Shockley RK, Jay WM, Fishman PH, Aziz MZ, Rissing JP: Effect of inoculum size on the induction of endophthalmitis in aphakic rabbit eyes. Acta Ophthalmol 1985;63:35–38.
96.
Meredith TA, Trabelsi A, Miller MJ, Aguilar E, Wilson LA: Spontaneous sterilization in experimental Staphylococcus epidermidis endophthalmitis. Invest Ophthalmol Vis Sci 1990;31:181–186.
97.
Saez-Llorens X, Ramilo O, Mustafa MM, McCraken GH Jr: Molecular pathophysiology of bacterial meningitis: Current concepts and therapeutic implications. J Pediatr 1990;116:671–684.
98.
Quagliarello V, Scheld WM: Bacterial meningitis: Pathogenesis, pathophysiology, and progress. N Engl J Med 1992;327:864–872.
99.
Maxwell DP, Brent BD, Orillac R, Baber WB, Mayeux PA: A natural history study of experimental Staphylococcus epidermidis endophthalmitis. Curr Eye Res 1993;12:907–912.
100.
Engstrom RE, Mondino BJ, Glasgow BJ, Pitchekian-Halabi H, Adamu SA: Immune response to Staphylococcus aureus endophthalmitis in a rabbit model. Invest Ophthalmol Vis Sci 1991;32:1523–1533.
101.
Pleyer U, Mondino BJ, Adamu SA, Pitchekian-Halabi H, Engstrom RE, Glasgow BJ: Immune response to Staphylococcus epidermidis-induced endophthalmitis in a rabbit model. Invest Ophthalmol Vis Sci 1992;33:2650–2663.
102.
Franklin RM, McGee DW: A mechanism for immunoglobulin-A plasma cell lodging in the lacrimal gland; in O’Conner GR, Chandler JW (eds): Advances in Immunology and Immunopathology of the Eye. Chicago, Year Book Medical, 1985, pp 186–190.
103.
Ravindranath RMH, Mondino BJ, Adamu SA, Pitchekian-Halabi H, Hasan SA, Glasgow BJ: Immunopathologic features of Staphylococcus aureus endophthalmitis in the rat. Invest Ophthalmol Vis Sci 1995;36:2482–2491.
104.
Ravindranath RMH, Hasan SA, Mondino BJ: Immunopathologic features of Staphylococcus epidermidis-induced endophthalmitis in the rat. Curr Eye Res 1997;16:1036–1043.
105.
Mondino BJ, Sidikaro Y, Sumner H: Anaphylatoxin levels in human vitreous humor. Invest Ophthalmol Vis Sci 1988;29:1195–1198.
106.
Mondino BJ, Glovsky MM, Ghekiere L: Activated complement in inflamed aqueous humor. Invest Ophthalmol Vis Sci 1984;25:871–873.
107.
Mondino BJ, Sidikaro Y, Mayer FJ, Sumner HL: Inflammatory mediators in the vitreous of AIDS patients with retinitis. Invest Ophthalmol Vis Sci 1990;31:798–804.
108.
Aizuss DA, Mondino BJ, Sumner HL, Dethlefs BA: The complement system and host defense against Pseudomonas endophthalmitis. Invest Ophthalmol Vis Sci 1985;26:1262–1266.
109.
Giese MJ, Mondino BJ, Glasgow BJ, Sumner HL, Adamu SA, Halabi HP, Chou HJ: Complement system and host defense against staphylococcal endophthalmitis. Invest Ophthalmol Vis Sci 1994;35:1026–1032.
110.
De Vos AF, Hoekzema R, Kijlstra A: Cytokines and uveitis, a review. Curr Eye Res 1992;11:581–597.
111.
Kunkel SL, Lukacs N, Strieter RM: Cytokines and inflammatory disease; in Sirica AE (ed): Cellular and Molecular Pathogenesis. Philadelphia, Lippincott-Raven Press, 1996, pp 23–38.
112.
Giese MJ, Sumner HL, Berliner JA, Mondino BJ: Cytokine expression in a rat model of Staphylococcus aureus endophthalmitis. Invest Ophthalmol Vis Sci 1998;39:2785–2790.
113.
Guex-Crosier Y, Wittwer AJ, Roberge FG: Intraocular production of a cytokine (CINC) responsible for neutrophil infiltration in endotoxin induced uveitis. Br J Ophthalmol 1996;80:649–653.
114.
Durum SK, Oppenheim JJ: Proinflammatory cytokines and immunity; in Paul WE (ed): Fundamental Immunology, ed 3. New York, Raven Press, 1993, pp 801–835.
115.
Yoshida M, Yoshimura N, Hangai M, Tanihara H, Honda Y: Interleukin-1α, interleukin-1β, and tumor necrosis factor gene expression in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1994;35:1107–1113.
116.
Yang R, De Vos AF, Kijlstra A: Macrophages in the retina of normal Lewis rats and their dynamics after injection of lipopolysaccharide. Invest Ophthalmol Vis Sci 1996;37:77–85.
117.
Planck SR, Huang XN, Robertson JE, Rosenbaum JT: Cytokine mRNA levels in rat ocular tissues after systemic endotoxin treatment. Invest Ophthalmol Vis Sci 1994;35:924–930.
118.
Fisher BM, Fleisher LN, Tompkins W, Ma J, McGahan MC: Endotoxin induced tumor necrosis factor like activity from bovine hyalocytes. ARVO abstract No 2106. Invest Ophthalmol Vis Sci 1992;33:S1114.
119.
Yoshihara R, Shiozawa S, Fujita T, Chihara K: Gamma interferon is produced by human natural killer cells but not T cells during Staphylococcus aureus stimulation. Infect Immun 1993;61:3117–3122.
120.
Booth MC, Hatter KL, Miller D, Davis J, Kowalski R, Parke DW, Chodosh J, Jett BD, Callegan MC, Penland R, Gilmore MS: Molecular epidemiology of Staphylococcus aureus and Enterococcus faecalis in endophthalmitis. Infect Immun 1998;66:356–360.
121.
Peyman GA, Vastine DW, Raichand M: Symposium: Post-operative endophthalmitis, experimental aspects and their clinical application. Ophthalmology 1978;85:374–385.
122.
Beecher DJ, Pulido JS, Barney NP, Wong ACL: Extracellular virulence factors in Bacillus cereus endophthalmitis: Methods and implication of involvement of hemolysin BL. Infect Immun 1995;63:632–639.
123.
Beecher DJ, Olsen TW, Somers EB, Wong ACL: Evidence for contribution of tripartite hemolysin BL, phosphatidylcholine-preferring phospholipase C, and collagenase to virulence of Bacillus cereus endophthalmitis. Infect Immun 2000;68:5269–5276.
124.
Jett BD, Jensen HG, Nordquist RE, Gilmore MS: Contribution of the pAD1-encoded cytolysin to the severity of experimental Enterococcus faecalis endophthalmitis. Infect Immun 1992;60:2445–2452.
125.
Stevens SX, Jensen HG, Jett BD, Gilmore MS: A hemolysin-encoding plasmid contributes to bacterial virulence in experimental Enterococcus faecalis endophthalmitis. Invest Ophthalmol Vis Sci 1992;33:1650–1656.
126.
Callegan MC, Engel LS, Hill JM, O’Callaghan RJ: Corneal virulence of Staphylococcus aureus: Roles of alpha-toxin and protein A in pathogenesis. Infect Immun 1994;62:2478–2482.
127.
O’Callaghan RJ, Callegan M, Moreau JM, Green LC, Foster TJ, Hartford OM, Engel LS, Hill JM: Specific roles of alpha-toxin and beta-toxin during Staphylococcus aureus corneal infection. Infect Immun 1997;65:1571–1578.
128.
Siqueira JA, Speeg-Schatz C, Freitas FI, Sahel J, Manteil H, Prévost G: Channel-forming leukotoxins from Staphylococcus aureus cause severe inflammatory reaction in a rabbit model. J Med Microbiol 1997;46:486–494.
129.
Supersac S, Piémont Y, Kubina M, Prévost G, Foster TJ: Assessment of the role of gamma-toxin in experimental endophthalmitis using a hlg-deficient mutant of Staphylococcus aureus. Microb Pathog 1998;24:241–251.
130.
Booth MC, Atkuri RV, Nanda SK, Iandolo JJ, Gilmore MS: Accessory gene regulator controls Staphylococcus aureus virulence in endophthalmitis. Invest Ophthalmol Vis Sci 1995;36:1828–1836.
131.
Booth MC, Cheung AL, Hatter KL, Jett BD, Callegan MC, Gilmore MS: Staphylococcal accessory regulator [sar] in conjunction with agr contributes to Staphylococcus aureus virulence in endophthalmitis. Infect Immun 1997;65:1550–1556.
132.
Callegan MC, Booth MC, Jett BD, Gilmore MS: Pathogenesis of gram-positive bacterial endophthalmitis. Infect Immun 1999;67:3348–3356.
133.
Kim IT, Park SK, Lim JH: Inflammatory response in experimental Staphylococcus and Pseudomonas endophthalmitis. Ophthalmologica 1999;21:305–310.
134.
Giese MJ, Berliner JA, Riesner A, Wagar EA, Mondino BJ: A comparison of the early inflammatory effects of agr–/sar– versus a wild type strain of Staphylococcus aureus in a rat model of endophthalmitis. Curr Eye Res 1999;18:177–185.
135.
Babior BM: Phagocytes and oxidative stress. Am J Med 2000;109:33–44.
136.
Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994;76:301–314.
137.
Giese MJ, Shum DC, Rayner SA, Mondino BJ, Berliner JA: Adhesion molecule expression in a rat model of Staphylococcus aureus endophthalmitis. Invest Ophthalmol Vis Sci 2000;41:145–153.
138.
Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B: Endothelial leukocyte adhesion molecule-1: An inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 1989;243:1160–1165.
139.
Pober JS, Gimbrone MA Jr, Lapierre LA, Mendrick DL, Fiers W, Rothlein R, Springer TA: Overlapping patterns of activation of human endothelial cells by interleukin-1, tumor necrosis factor and immune interferon. J Immunol 1986;137:1893–1896.
140.
Darveau RP, Cunningham MD, Bailey T, Seachord C, Ratcliffe K, Bainbridge B, Diesch M, Page RC, Aruffo A: Ability of bacteria associated with chronic inflammatory disease to stimulate E-selectin expression and promote neutrophil adhesion. Infect Immun 1995;63:1311–1317.
141.
Kawamura N, Imanishi N, Koike H, Nakahara H, Phillips L, Morooka S: Lipoteichoic acid-induced neutrophil adhesion via E-selectin to human umbilical vein endothelial cells (HUVECs). Biochem Biophys Res Commun 1995;217:1208–1215.
142.
Noel RF Jr, Sato TT, Mendez C, Johnson MC, Pohlman TH: Activation of human endothelial cells by viable or heat-killed gram-negative bacteria requires soluble CD14. Infect Immun 1995;63:4046–4053.
143.
Krüll M, Dold C, Hippenstiel S, Rosseau S, Lohmeyer J, Suttorp N: Escherichia coli hemolysin and Staphylococcus aureus α-toxin potentially induce neutrophil adhesion to cultured endothelial cells. J Immunol 1996;157:4133–4140.
144.
Yao L, Lowy FB, Berman JW: Interleukin-8 gene expression in Staphylococcus aureus- infected endothelial cells. Infect Immun 1996;64:3407–3409.
145.
Henderson B, Wilson M: Cytokine induction by bacteria: Beyond lipopolysaccharide. Cytokine 1996;8:269–282.
146.
Ferrante A, Staugas REM, Rowan-Kelly B, Bresatz S, Kumaratilake LM, Rzepczyk CM, Adolf GR: Production of tumor necrosis factors alpha and beta by human mononuclear leukocytes stimulated with mitogens, bacteria, and malarial parasites. Infect Immun 1990;58:3996–4003.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.